Lawson Kroeker Investment Management Inc. NE Sells 80,550 Shares of Bruker Corporation $BRKR

Lawson Kroeker Investment Management Inc. NE lowered its stake in Bruker Corporation (NASDAQ:BRKR) by 38.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,535 shares of the medical research company’s stock after selling 80,550 shares during the quarter. Bruker comprises 1.8% of Lawson Kroeker Investment Management Inc. NE’s portfolio, making the stock its 23rd biggest holding. Lawson Kroeker Investment Management Inc. NE owned 0.09% of Bruker worth $6,197,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after acquiring an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Bruker during the first quarter valued at approximately $262,000. Goldman Sachs Group Inc. boosted its position in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after purchasing an additional 758,301 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after purchasing an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth increased its stake in shares of Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after purchasing an additional 6,008 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at $7,064,365. This trade represents a 5.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold 11,000 shares of company stock worth $554,280 over the last three months. 27.30% of the stock is currently owned by corporate insiders.

Bruker Stock Performance

BRKR opened at $36.76 on Friday. The stock has a market capitalization of $5.60 billion, a price-to-earnings ratio of -245.07, a PEG ratio of 2.20 and a beta of 1.20. The company has a fifty day moving average of $38.60 and a 200 day moving average of $41.31. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. During the same quarter in the previous year, the firm earned $0.76 EPS. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, March 23rd. Bruker’s payout ratio is currently -133.33%.

Wall Street Analyst Weigh In

BRKR has been the topic of a number of analyst reports. The Goldman Sachs Group lowered their target price on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research note on Friday, February 13th. Jefferies Financial Group set a $50.00 price target on Bruker in a report on Thursday, February 12th. Bank of America boosted their price objective on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Zacks Research raised Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. Finally, Citigroup decreased their target price on Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Bruker currently has a consensus rating of “Hold” and an average price target of $49.77.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.